Medopad is a well known British health technology company that is monitoring patient vital signs by using apps and wearables. Sherbit is currently based in San Francisco that earns money through subscriptions of hospitals, an app offering to patients in order to maintain and identify their vital signs. Now that Medopad has made its move, it is likely that the two CEOs Alex Senemar and Dan Vahdat of Sherbit and Medopad respectively will act accordingly to match the industry’s needs. Although the Financial terms of the deal were not disclosed, it is highly possible that we might get some news on it in the future.
The Major role played here is the data that is very much essential for these companies and doctors to diagnose accurately. Presently, the deal is clearly consolidating the health tech startup. With enough data, the patient at risk will be cured in no time. Through the company’s quick blood pressure monitoring, blood glucose analysis and wearable devices, the company is really said to make a huge difference in the healthcare market.
"Spotting any complications before they arise, Sherbit is the first step for us in the U.S.", Medopad CEO Dan Vahdat said in a press release. Surely this might make some changes in the healthcare division, let us see what happens in the future.